AI-generated from publicly available materials.Novalix and OpenBench have announced a strategic partnership aimed at revolutionizing the drug discovery process by offering AI-validated chemical hit series through a fee-for-success model.
In this collaboration, OpenBench will initially screen vast libraries of compounds, identifying and synthesizing the most promising candidates. These hits will then be handed over to Novalix, which will utilize its in vitro screening capabilities to refine these candidates into actionable starting points for challenging drug targets. Notably, OpenBench will shoulder the financial and scientific risks during the early stages, charging clients only upon successful delivery of validated hits.
This innovative approach addresses significant inefficiencies in traditional drug discovery, where high-throughput screening often leads to misleading results due to factors like nonspecific binding and poor cellular permeability. Industry estimates suggest that up to 40% of researchers' time is wasted on data validation rather than actual experimentation, contributing to the rising costs of drug development, which now average around $2.67 billion per molecule. The partnership aims to streamline this process, potentially delivering validated hits in as little as six months, thus allowing clients to allocate resources more effectively within Novalix's comprehensive drug development pipeline.
The collaboration between Novalix and OpenBench represents a significant step towards enhancing R&D productivity in the life sciences sector. By integrating AI-driven discovery with robust experimental validation, the partnership promises to mitigate the uncertainties and financial burdens typically associated with early-stage drug development, offering life science companies a more efficient pathway to viable chemical starting points.